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Introduction
Molecular oxygen is essential for the survival of all aerobic
organisms. Aerobic energy generation is dependent on
oxidative phosphorylation, a process by which the
oxidoreduction energy of mitochondrial electron transport
is converted to the high-energy phosphate bond of ATP. In
this multi-step enzymatic process, oxygen serves as the
final electron acceptor for cytochrome c oxidase, the
terminal component of the mitochondrial enzymatic
complex that catalyzes the four-electron reduction of O2 to
H2O. A byproduct of this process is the production of
partly reduced oxygen metabolites that are highly reactive
and that leak out of the mitochondria and react rapidly
with other molecules. In turn, reactive nitrogen species,
sulfur-centered radicals, and other reactive species are
generated by interactions with these molecules. Reactive
oxygen species (ROS) participate in several physiological
functions, and form an integral part of the organism’s
defense against invading microbial agents.
Because of their potentially damaging effects, several
antioxidant mechanisms have evolved to protect cells and
organisms from damage by excessive amounts of these
highly reactive mediators. Oxidative stress is a term that is
used to describe situations in which the organism’s
production of oxidants exceeds the capacity to neutralize
them. The result can be damage to cell membranes, lipids,
nucleic acids, proteins, and constituents of the
extracellular matrix such as proteoglycans and collagens.
Extended periods of hypoxia, or brief periods of complete
anoxia, invariably lead to death. In contrast, cellular hypoxia
occurs frequently, both physiologically and pathologically,
and serves as a potent stimulus for changes in gene
transcription, translation, and several post-translational
protein modifications that serve to rapidly adapt cells and
tissues to this stimulus. Oxygen levels vary considerably in
different tissues — and even in different areas of a single
tissue — and depend on a complex interaction of
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Abstract
Oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis. Reactive oxygen
species (ROS) produced in the course of cellular oxidative phosphorylation, and by activated
phagocytic cells during oxidative bursts, exceed the physiological buffering capacity and result in
oxidative stress. The excessive production of ROS can damage protein, lipids, nucleic acids, and
matrix components. They also serve as important intracellular signaling molecules that amplify the
synovial inflammatory–proliferative response. Repetitive cycles of hypoxia and reoxygenation
associated with changes in synovial perfusion are postulated to activate hypoxia-inducible factor-1α
and nuclear factor-κB, two key transcription factors that are regulated by changes in cellular
oxygenation and cytokine stimulation, and that in turn orchestrate the expression of a spectrum of
genes critical to the persistence of synovitis. An understanding of the complex interactions involved in
these pathways might allow the development of novel therapeutic strategies for rheumatoid arthritis.
Keywords: hypoxia, oxidation, rheumatoid arthritis, synovitis266
Arthritis Research & Therapy    Vol 6 No 6 Hitchon and El-Gabalawy
physiological variables, particularly the balance between
the vascular supply and the metabolic demands of the
tissue. Hypoxia serves as a particularly potent stimulus for
angiogenesis in most tissues.
In this review we explore the role of oxidative stress and
hypoxia in the pathogenesis of rheumatoid arthritis (RA), a
prototypical chronic inflammatory disorder, focusing on
recent developments in this area, and highlighting
mechanisms that can potentially be exploited
therapeutically. An understanding of these processes in
the context of RA has been greatly aided by knowledge
gained in the areas of cancer and cardiovascular biology.
ROS in health and disease
Generation of ROS
Phagocytic cells such as macrophages and neutrophils,
on activation, undergo an oxidative burst that produces
highly toxic ROS that are designed to kill the invading
pathogens (reviewed in [1,2]). This oxidative burst is
mediated by the NADPH oxidase system, and results in a
marked increase in oxygen consumption and the
production of superoxide (O2
–•). NADPH is composed of
several subunits that assemble at the plasma membrane
and fuse with intracellular phagocytic vesicles or the outer
membrane. This allows the concentrated release of
oxidants formed subsequently. Superoxide is converted to
hydrogen peroxide (H2O2) either spontaneously or more
rapidly when catalyzed by superoxide dismutatase, an
enzyme that occurs in two isoforms, one of which is
inducible by inflammatory cytokines such as tumor
necrosis factor-α (TNF-α).
In the presence of ferrous ions (Fe2+) and other transition
metals, hydrogen peroxide and superoxide are converted
via the Fenton reaction to highly reactive, aqueous soluble
hydroxyl radicals (OH•) that are probably responsible for
much of the cell toxicity associated with ROS.
Additionally, the neutrophil-associated enzyme myeloper-
oxidase can oxidize halides such as chloride (Cl–) and
convert hydrogen peroxide into hypochlorous acid (HOCl),
which then can interact with amino acids to form
chloramines. Similar reactions can occur with other
halides such as bromide and iodide. Further reaction of
hydrogen peroxide with hypochlorous acid produces
singlet oxygen, another highly reactive and damaging
radical. Reactions of hypochlorous acid with amino acids
lead to aldehyde production. Superoxide can also react
with nitric oxide (NO), synthesized from the deimination of
L-arginine by nitric oxide synthase (NOS), and produce the
highly reactive peroxynitrite radical (ONOO–). These
reactions are summarized in Table 1.
Physiological roles for ROS
ROS are produced during normal aerobic cell metabolism,
have important physiological roles in maintaining cell redox
status, and are required for normal cellular metabolism
including intracellular signaling pathways and the activity
of transcription factors such as NF-κB, activator protein 1
and hypoxia-inducible factor-1α (HIF-1α) (see below). In
addition, ROS produced by phagocytes also seem to have
important physiological roles in priming the immune system.
A functional mutation of a component of the NADPH
oxidase complex, Ncf1, produces a lower oxidative burst
and enhanced arthritis susceptibility and severity in murine
pristane-induced arthritis [3,4]. Activation of the NADPH
complex by vitamin E ameliorated arthritis when given
before arthritis induction, indicating that the Ncf1
functional polymorphism is involved at the immune priming
stage of disease. The authors of those papers propose
that the physiological production of ROS by phagocytes in
response to antigen affects T cell–antigen interactions
and possibly induces apoptosis of autoreactive
arthritogenic T cells, thereby preventing autoimmune
responses. In humans, Ncf1 is redundant and a complete
loss of function is associated with chronic granulomatous
disease that has increased susceptibility to microbial
infections. The associations of Ncf1 with other
experimental autoimmune conditions suggest that
polymorphisms in the Ncf1 gene might be important for
autoimmunity in general [5].
Oxidant defense mechanisms
Several defense mechanisms have evolved to protect
cellular systems from oxidative damage. These include
intracellular enzymes such as superoxide dismutase,
glutathione peroxidase, catalase and other peroxidases,
thioredoxin reductase, the sequestration of metal ion
cofactors such as Fe and Cu by binding to proteins, and
endogenous antioxidants. Superoxide dismutase (SOD)
enhances the otherwise slow spontaneous breakdown of
superoxide, forming the less toxic hydrogen peroxide,
which can then interact with glutathione and ultimately
form H2O and O2. SOD exists in a constitutively
expressed form and an inducible form (MnSOD) that
resides in mitochondria. MnSOD is induced by cytokines
through NF-κB and may require other cofactors including
nucleolar phosphosmin, an RNA-binding protein [6].
Glutathione peroxidase, the primary mitochondrial defense
from hydrogen peroxide, is upregulated by p53 and
hypoxia [7,8]. Catalase also degrades hydrogen peroxide,
and probably has a function in cytosolic or extracellular
protection from oxidants because it is absent from the
mitochondria of most cells. The thioredoxin–thioredoxin
reductase system is another essential component of the
cellular response to oxidative stress, especially in cardiac
tissue [9]. Several stressors, including inflammatory
cytokines and oxidative stress, induce thioredoxin.
Thioredoxin regulates protein redox status and, when
activated, facilitates protein–DNA interactions. In cardiac
tissue, thioredoxin expression is enhanced under
conditions of cyclic hypoxia and reperfusion. Enhanced267
thioredoxin expression has also been demonstrated in RA
synovial fluid and tissue [10–12].
Endogenous antioxidants protect cellular systems from the
damaging effects of ROS and reactive nitrogen species
(RNS) reviewed in [13]. The main antioxidants are vitamin
A (retinol and metabolites), vitamin C (ascorbic acid) and
vitamin E (α-tocopherol).  β-Carotene, a water-soluble
provitamin A, is a free-radical scavenger that controls the
propagation of reactive species and influences
lipoxygenase activity. Vitamin C (ascorbic acid), one of the
first lines of defense from oxidative stress, can prevent
lipid peroxidation by trapping water-soluble peroxyl
radicals before their diffusion into lipid membranes; it also
reacts with superoxide, peroxy, and hydroxyl radicals, and
is important in recycling other antioxidants such as vitamin
E. Vitamin E has lipid-soluble properties that allow it to act
as a chain-breaking reagent in lipid peroxidation.
Evidence for oxidative stress in RA
Several lines of evidence suggest a role for oxidative
stress in the pathogenesis of RA. Epidemiologic studies
have shown an inverse association between dietary intake
of antioxidants and RA incidence [14–17], and inverse
associations between antioxidant levels and inflammation
have been found [18,19]. Iron, a catalyst for hydroxyl
radical production from hydrogen peroxide (see Table 1),





NADPH oxidase: 2O2 + NADPH → 2O2
•– (superoxide) + NADPH+ + H+
Spontaneous conversion: 2O2
•– + 2H+ → [2HO2
• (hydroperoxyl radical)]→ O2 + H2O2
Superoxide dismutase: 2O2
•– + 2H+ → O2 + H2O2
Myeloperoxidase: Cl– + H2O2 → OCl– (oxidised halide) + H2O
Reactive oxygen species secondary products
H2O2 + Fe2+ → OH– + OH • (hydroxyl radical) + Fe3+
Fe3+ + O2
•– → O2 + Fe2+
O2
•– + HOCl → O2
•– + OH• + Cl–
H2O2 + OCl– → 1O2 (singlet oxygen) + H2O + Cl–
NH3 + HOCl → NH2Cl (chloramine) +H2O
R-CHNH2-COOH + HOCl → R-CHNHCl–COOH +H2O → R-CHO + CO2 + NH4
+ + Cl–
(amino acids) (chloramines) (aldehydes)
Nitrogen radical generation and secondary reactions
Nitric oxide synthetase: arginine + O2 + NADPH → NO• + citrulline + NADP+
NO• + O2
•– → ONOO– (peroxynitrite)
ONOO– + H+ → ONOOH (peroxynitrous acid)
ONOOH (peroxynitrous acid) → NO3
– (nitrate ion)
ONOOH → NO2+ (nitronium ion)
ONOOH → NO2
• (nitrogen dioxide radical)
ONOOH → OH–
ONOOH → OH• (hydroxyl radical)
Lipid peroxidation
LH + Radical• → L• + RH
L• + O2 → LOO• (lipid peroxyl radical)
LH + LOO• → L• + LOOH (leading to lipid propagation)
LOO• + TocOH (α-tocopherol) → LOOH + TocO• (chain termination)268
poorer prognosis [20]. Several groups have demonstrated
increased oxidative enzyme activity along with decreased
antioxidant levels in RA sera and synovial fluids [21–25].
Because of the highly reactive nature of ROS, it is difficult
to directly demonstrate their presence in vivo. It is
considerably more practical to measure the ‘footprints’ of
ROS and RNS, such as their effects on various lipids,
proteins, and nucleic acids. Thus, evidence for oxidative
stress in RA has in many cases been generated by
approaches that detect oxidant-induced changes to these
molecules (reviewed in [1,26–28]). Studies of RA synovial
fluid and tissue have demonstrated oxidative damage to
hyaluronic acid [29], lipid peroxidation products [30,31],
oxidized low-density-lipid proteins (LDL) [32], and
increased carbonyl groups reflective of oxidation damage
to proteins [32,33]. Evidence of oxidative damage to
cartilage, extracellular collagen, and intracellular DNA has
also been demonstrated (see below). Oxidative stress has
been shown to induce T cell hyporesponsiveness in RA
through effects on proteins and proteosomal degradation
[34]. Finally, antioxidants and oxidative enzymes have been
shown to ameliorate arthritis in animal models [35–37].
Cartilage/collagen effects
ROS and RNS damage cellular elements in cartilage
directly and damage components of the extracellular
matrix either directly or indirectly by upregulating
mediators of matrix degradation (reviewed in [2,26]).
Modification of amino acids by oxidation, nitrosylation,
nitration, and chlorination can alter protein structure and
impair biological function, leading to cell death. ROS
impair chondrocyte responses to growth factors and
migration to sites of cartilage injury; RNS, in particular NO,
interfere with interactions between chondrocytes and the
extracellular matrix [38]. NO can also increase
chondrocyte apoptosis.
Oxygen and nitrogen radicals inhibit the synthesis of
matrix components including proteoglycans by chondro-
cytes. In particular, NO and O2 seem to inhibit type II
collagen and proteoglycan synthesis and the sulfation of
newly synthesized glycosaminoglycans. Oxygen radicals
can cause low levels of collagen fragmentation and
enhanced collagen fibril cross-linking. Oxygen radicals
have also been shown to fragment hyaluronan and
chondroitin sulfate [39,40] and damage the hyaluronan-
binding region of the proteoglycan core protein, thereby
interfering with proteoglycan–hyaluronan interactions [41].
In addition, ROS and RNS can damage the components
of the extracellular matrix indirectly through the activation
and upregulation of matrix metalloproteinases.
Oxidative damage to immunoglobulins – advanced
glycation end-products
Oxidative stress occurring during inflammation can cause
proteins to become non-enzymatically damaged by
glyoxidation. This process, which involves primarily lysine
and arginine residues, ultimately results in the generation
of advanced glycation endproducts (AGE), which are
stable. An example of this process is the glyoxidation of
hemoglobin to hemoglobin A1c in the context of repetitive
hyperglycemia. The immunoglobin molecule can also
undergo similar glyoxidation to generate AGE-IgG. In the
context of inflammatory arthritis, we have shown that
antibodies to AGE-IgG are specifically associated with
RA, whereas the actual formation of AGE-IgG is related to
the intensity of the systemic inflammatory response, and is
not specific to RA [42,43].
Genotoxic effects of oxidative stress
Reactive oxygen and nitrogen species directly damage
DNA and impair DNA repair mechanisms. This damage
can occur in the form of DNA strand breakage or
individual nucleotide base damage. DNA reaction products,
in particular 8-oxo-7-hydro-deoxyguanosine formed by the
reaction of hydroxyl radicals (OH•) with deoxyguanosine,
are elevated in leukocytes and sera of patients with RA
[44,45]. This product is particularly mutagenic and
cytotoxic. NO, especially in high concentrations, causes
the deamination of deoxynucleotides, DNA strand
breakage and oxidative damage from peroxynitrite, and
DNA modification by metabolically activated N-
nitrosamines, all of which can lead to somatic mutations.
RA tissue has evidence of microsatellite instability
reflecting ongoing mutagenesis [46]. Such mutagenesis is
normally corrected by DNA repair systems including the
mismatch repair (MMR) system; however, the MMR
system is defective in RA, probably due in part to oxidative
stress. Evidence for this comes from findings of
decreased expression of hMSH6, a component of the
MutSα complex that is important for repair of the single
base mismatches that are characteristic of oxidative
stress, and increased expression of hMSH3, a component
of MutSβ that is important for the repair of insertion or
deletion loops. This pattern of MMR expression was
reproduced by synovial fibroblasts exposed to reactive
nitrate species and to a smaller extent by fibroblasts
exposed to ROS, indicating a role for oxidative stress in
the development of microsatellite instability in RA. The
authors of this work suggest that this pattern of MMR
expression might allow short-term cell survival by
preventing potentially major DNA damage at the expense
of minor DNA damage or that it might promote the
development of a mutated phenotype having additional
survival benefit.
Although somatic DNA mutations probably occur
randomly through the genome, they may occur in the
coding regions of functional genes. An example of this is
the p53 tumor suppressor gene. The p53 tumor
suppressor protein is important in containing and repairing
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mutations through its effects on growth regulating genes,
G1 growth arrest, interactions with DNA repair
mechanisms, and apoptosis. In addition, wild-type p53
downregulates NOS and subsequent NO production
through interaction with the region of the NOS2 promoter
[47]. Somatic mutations of p53 have been demonstrated
in RA synovium and cultured RA fibroblast-like synovio-
cytes [48,49], and have been implicated in the
pathogenesis of inflammatory arthritis [28]. These are
primarily transitional mutations consistent with mutations
resulting from oxidative deamination by nitric oxide or
oxygen radicals, and are similar to those found in tumors.
Importantly, there is a distinct geographical distribution of
the mutations in RA synovium [50]. The distribution of p53
mutations was patchy, with most being located in the
lining layer, an area distant from oxygenating vasculature
and bathed in oxidant-rich synovial fluid. Specific
histologic correlation was not provided; however, it is
interesting to speculate that the areas with a high
frequency of p53 mutations might also have lining layer
hyperplasia and that these mutations contribute to the
formation of the invasive pannus.
Mitochondrial DNA (mtDNA) is particularly susceptible to
oxidative stress, and prolonged exposure leads to
persistent mtDNA damage without effective repair, loss of
mitochondrial function, cell growth arrest, and apoptosis
[51]. This increased susceptibility probably relates to the
proximity of mtDNA to oxidative reactive species including
the lipid peroxidation products generated from inner mito-
chondrial membrane lipids, which contain components of
the respiratory electron transport chain, or a lack of
protecting histones, or potentially inefficient repair
mechanisms. The relevance of mtDNA to inflammatory
arthritis is found from studies demonstrating that
extracellular mtDNA is increased in RA synovial fluid and
plasma [45] and that oxidatively damaged mtDNA can
induce murine arthritis [52].
Lipid peroxidation
Lipid peroxidation has been implicated in the patho-
genesis of cancer, atherosclerosis, degenerative diseases,
and inflammatory arthritis. During lipid peroxidation,
polyunsaturated fatty acids are oxidized to produce lipid
peroxyl radicals that in turn lead to further oxidation of
polyunsaturated fatty acid in a perpetuating chain reaction
that can lead to cell membrane damage (see Table 1).
Matrix degradation arising from cytokine-stimulated
chondrocytes was shown to be primarily due to lipid
peroxidation, and to be preventable by vitamin E, the
primary antioxidant for lipids [53].
Lipid oxidation probably contributes to accelerated athero-
sclerosis in RA [54–56]. Persistent local and systemic
elevation of inflammatory cytokines promotes lipolysis, and
the systemic release of free fatty acids contributes to the
dyslipidemia seen in RA. Oxidative stress arising from
inflammatory reactions leads to the oxidation of local LDL.
Oxidized LDL promotes further inflammatory changes,
including local upregulation of adhesion molecules and
chemokines. Advanced glycation endproducts might also
contribute to this inflammation. Monocytes ingest large
quantities of oxidized LDL, resulting in the formation of
foam cells that are present in atherosclerotic plaques of
vessels and have also been found in RA synovial fluid [57]
and synovium [58].
Role of hypoxia and reoxygenation in RA
synovitis
Several lines of evidence have suggested that cycles of
hypoxia/reoxygenation are important in sustaining RA
synovitis. It has long been known that RA synovial fluids
are hypoxic, acidotic, and exhibit low glucose and elevated
lactate concentrations [59,60]. This biochemical profile is
indicative of anaerobic metabolism in the synovium [61,62].
We have recently repeated the seminal experiments
evaluating pO2 levels in RA synovial fluids and found that
the pO2 levels are frequently below those detected in
venous blood, with some being as low as 10 mmHg (CAH
and HSE-G, unpublished work). These levels correlated
with lactic acid levels. It has proven more difficult to
measure pO2 levels in RA synovium directly in vivo. Two
studies, published in abstract form, evaluated RA synovial
pO2 with microelectrodes and found these levels to be
quite low [63,64]. These data are supported by similar
findings in experimental inflammatory arthritis [65];
together they support the notion that RA synovitis has the
features of a chronically hypoxic microenvironment that
compensates by using anaerobic metabolism.
Cellular responses to hypoxia: the role of HIF-1α α
The potential role of hypoxia in RA synovitis has largely
been extrapolated from studies of tumors, in which the
rapidly proliferative state and high metabolic demands of
the tumor cells result in areas of hypoxia generated by an
imbalance between the demands and the abnormal tumor
vascular supply. This hypoxic microevironment potently
stimulates tumor angiogenesis and results in phenotypic
changes in the tumor cells that favor survival and growth in
this environment [66,67]. The biological basis of this
process has been well studied, and relates to the exquisite
regulation of a key transcription factor, HIF-1α [68]. This
oxygen-sensitive transcription factor orchestrates the
expression of a wide spectrum of genes that serve, first, to
allow the cells to use anaerobic metabolism to generate
energy; second, to enhance survival and inhibit apoptosis;
and third, to improve the supply of oxygen by promoting
angiogenesis and increased oxygen-carrying capacity.
In view of the crucial role of HIF-1α in cellular adaptation
to hypoxia, its regulation needs to be rapidly responsive to
changes in the cellular oxygen supply. Although several
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mechanisms have been proposed for oxygen sensing, it
has been shown that the primary mechanism by which
hypoxia directly regulates HIF-1α is by inhibiting its
degradation [68]. Under aerobic conditions HIF-1α is
undetectable because of a rapid process of ubiquitination
and subsequent proteosomal degradation. This
degradative process is mediated by von Hippel–Landau
tumor suppressor factor (VHL) [69,70], which when
mutated results in von Hippel–Landau syndrome,
characterized by the formation of hemangiomas due to
uninhibited angiogenesis. The interaction between HIF-1α
and VHL requires the critical hydroxylation of two proline
residues (402 and 564) and one asparagine residue
(803), as well as the acetylation of a lysine residue (532)
in HIF-1α [71,72]. The hydroxylation events are mediated
by a family of three prolyl hydroxylases (PHD-1, PHD-2,
and PHD-3) and one asparagine hydroxylase (FIH), and
require O2 and several cofactors, particularly iron and
ascorbate (Fig. 1). In the absence of O2, this critical
hydroxylation becomes rate limiting, thus preventing HIF-
1α from being degraded and leaving it free to bind to its
constitutively expressed partner, HIF-1β (aryl hydrocarbon
nuclear translocator; ARNT).
It should be noted that the degradation of HIF-1α can also
be inhibited by approaches that limit the availability of iron.
Thus, cobalt chloride (CoCl2), a competitive inhibitor, and
desferioxamine, an iron chelator, both potently stabilize
HIF-1α in vitro and mimic the effects of hypoxia. HIF-1α/
ARNT form a complex with CBP/p300, and this complex
rapidly translocates to the nucleus and transactivates
genes that have a hypoxia-responsive element (HRE) in
their promoters featuring the consensus motif RCGTG.
Although the full complement of HRE-regulated genes are
obviously present in all cells, the hypoxia-induced
expression of some of these genes, such as erythro-
poietin, is quite tissue specific. Other genes, such as
vascular endothelial growth factor (VEGF), and genes
encoding for glycolytic enzymes, are induced by hypoxic
stimulation in most cells. It is interesting to speculate that
glucose-6-phosphate isomerase, which as been proposed
as an autoantigen in RA [73–75], is induced by hypoxia in
a HIF-1α-dependent manner [76]. The list of genes that
have been shown to be directly regulated by HIF-1α is
shown in Fig. 2.
Thus, although there is now a well-defined group of genes
that are regulated by hypoxia through HIF-1α, their
patterns of expression vary in different cells and tissues.
Interestingly, it has recently been demonstrated that HIF-1α
is essential for the function of myeloid cells of the innate
immune systems such as neutrophils and macrophages
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Figure 1
Hypoxic regulation of the hypoxia-inducible factor-1α (HIF-1α) transcription factor is primarily through inhibition of degradation. Under normoxic
conditions, HIF-1α undergoes rapid proteosomal degradation once it forms a complex with von Hippel–Landau tumor suppressor factor (VHL) and
E3 ligase complex. This requires the hydroxylation of critical proline residues by a family of HIF-1α-specific prolyl hydroxylases (PHD-1,2,3), which
requires O2 and several cofactors, including iron. Under hypoxic conditions, or when iron is chelated or competitively inhibited, proline hydroxylation
does not occur, thus stabilizing HIF-1α and allowing it to interact with the constitutively expressed HIF-1β (aryl hydrocarbon nuclear translocator;
ARNT). The HIF-1 complex then translocates to the nucleus and activates genes with hypoxia-responsive elements in their promoters. bHLH, basic
helix-loop-helix; CBP, cAMP response element binding protein; FIH, factor inhibiting HIF-1α; PAS, PER-ARNT-SIM; TAD, transactivation domain.271
[77]. This study demonstrated that the regulation of
glycolytic capacity by HIF-1α in these myeloid cells is
crucial for the energy generation required for cell
aggregation, motility, invasiveness, and bacterial killing. Of
particular relevance to RA was the marked attenuation of
synovitis and articular damage in an adjuvant arthritis
model when HIF-1α was absent.
The effects of ROS on HIF-1α itself have been
controversial [78]. One hypothesis suggests that ROS are
produced by the NADPH oxidase system and serve to
inhibit HIF-1α activation [79]. During hypoxia, reduced
ROS formation serves to activate HIF-1α by diminished
inhibition. An alternative hypothesis suggests that ROS
are in fact produced by mitochondria during hypoxia and
may indeed serve to stabilize HIF-1α and promote nuclear
localization and gene transcription [80,81]. There is
experimental evidence in support of both of these
competing hypotheses, and indeed, both may be correct
depending on the intensity and duration of the hypoxic
stimulus, and on the cell type involved.
In addition to hypoxic regulation of HIF-1α, it has been
established that cytokines and growth factors such as
interleukin-1β (IL-1β), TNF-α, transforming growth factor-β
(TGF-β), platelet-derived growth factor, fibroblast growth
factor-2, and insulin-like growth factors are capable of
stabilizing and activating this key transcription factor under
normoxic conditions [82–87]. Several signaling pathways
are involved, particularly the phosphoinositide 3-kinase
(PI-3K)/Akt pathway, and the mitogen-activated protein
(MAP) kinase pathway. It is likely that the normoxic
regulation of HIF-1α by the PI-3K/Akt pathway involves
increased translation of the protein, whereas MAP kinase
regulation involves phosphorylation of the molecule, which
in turn increases its transactivating capacity [88,89]. The
regulation of HIF-1α by NO has also recently been shown
to be mediated by the MAP kinase and PI-3K/Akt
pathways [89].
HIF-1α α and hypoxia-regulated genes in RA synovitis
The expression of HIF-1α has been evaluated in RA and
other forms of synovitis [90–92]. One study suggested
that HIF-1α is widely expressed in RA synovium, and on
the basis of evaluating consecutive sections it was
assumed to be expressed in a cytoplasmic pattern by
macrophages in both the lining and sublining areas [92]. A
second study evaluated the expression of HIF-1α and the
related protein HIF-2α in RA, osteoarthritis, and normal
synovium, and found them to be widely expressed in both
RA and osteoarthritis but not in normal synovium [90]. The
synovial expression of HIF-1α in this study was in a mixed
nuclear and cytoplasmic pattern, and was seen in most
lining cells, stromal cells, mononuclear cells, and blood
vessels. On the basis of these findings, the authors
suggested a role for hypoxia and HIF-1α in the patho-
genesis of both RA and osteoarthritis.
Our own studies of synovial HIF-1α expression have
suggested a more limited, patchy pattern of nuclear
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Figure 2
Genes that have been shown to be directly regulated by hypoxia-inducible factor-1α through hypoxia-responsive elements in their promoter
regions. The genes are classified on the basis on their best known functional properties. A full listing of the gene annotations is presented in the
Additional file.272
expression that was confined primarily to the lining cells of
RA tissues with a particularly hyperplastic lining layer [91]
(Fig. 3). Indeed, when we exposed fresh synovial tissue
explants to hypoxic culture conditions, the nuclear
expression of HIF-1α increased markedly in the lining cell
layer, in a manner analogous to that seen in cultured
synovial fibroblasts. It should be noted that our
immunohistology studies were performed on snap-frozen
sections of synovium with the use of three commercially
available anti-HIF-1α antibodies. In contrast, the two other
studies used archival synovial tissue that had been
deparaffinized and then subjected to antigen retrieval
techniques. It is currently not clear whether these
technical considerations are sufficient to explain these
discrepant findings.
The presence of regional HIF-1α expression in hyper-
plastic areas of the RA lining layer would be consistent
with a dynamic process in which the lining cells in these
areas, being the furthest removed from a precarious and
insufficient vascular supply in the sublining areas, are
subjected to fluctuating oxygen levels, resulting in
repetitive cycles of hypoxia and reperfusion. Moreover,
such a regional distribution of HIF-1α expression would
also be in keeping with the known rapid stabilization and
nuclear translocation of HIF-1α under transient hypoxic
conditions, which is followed by equally rapid degradation
of this transcription factor when relative normoxia is re-
established [93].
The expression of several HIF-1α-regulated genes has
been explored in RA synovitis, in particular angiogenesis
mediators such as VEGF and the angiopoietins. VEGF has
been shown to be upregulated in the serum, synovial fluid,
and synovium of patients with RA [94–98]. Moreover,
clinical response to TNF-α inhibitors is associated with a
decrease in systemic and synovial VEGF levels, this being
attributed to inhibition of synovial angiogenesis [96,99]. At
the cellular level, the regulation of VEGF expression is
complex. We and others have shown that cytokines
abundant in RA synovium, such as TNF-α, IL-1β, and TGF-β,
interact with hypoxia in an additive manner to induce
VEGF expression by fibroblast-like synoviocytes [91,100].
The interaction at the level of the VEGF promoter between
HIF-1α and SMAD3, the latter being the mediator of TGF-β
transcriptional regulation, has been demonstrated [101].
Similarly, the angiopoietins Ang1 and Ang2, and their
cellular receptor Tie2, which are all widely expressed in
RA synovitis, are regulated by both hypoxia and TNF-α
[102–105]. These observations underscore the complexity
of transcriptional regulation in a chronic inflammatory
microenvironment such as RA synovium, and indicate that
the regulation of specific genes by hypoxia occurs in the
context of multiple other regulatory pathways, particularly
the NF-κB pathway.
Hypoxia, or hypoxia and reoxygenation?
Studies of RA synovium in vivo have suggested that
synovial perfusion is influenced directly by high intraarticular
pressures that are further increased by movement
[106–108]. On the basis of these observations, it can
therefore be proposed that intermittent joint loading with
ambulation, especially in the setting of an effused joint,
enhances local joint hypoxia, which in turn is followed by
reoxygenation when the joint is unloaded. A predicted
consequence of such cycles of hypoxia and reoxygenation
would be cycles of HIF-1α expression and the genes it
regulates, followed by repetitive bursts of ROS formation.
The ROS generated serve as a stimulus for NF-κB
activation, probably through effects on upstream kinases
[109,110]. This includes effects on the dissociation of
NF-κB from its inhibitor IκB (which requires oxidation), the
regulation of IκB degradation, and the binding of NF-κB to
DNA (which requires a reducing environment). Activation of
NF-κB serves to induce the expression of multiple
proinflammatory genes, many of which are also regulated by
HIF-1α [78,111]. This interaction is summarized in Fig. 4.
The resultant changes in gene and protein expression are
complex and vary in different cell types, but overall can be
expected to promote inflammation, angiogenesis, and
enhanced cell survival, all cardinal features of RA synovitis.
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Figure 3
Expression of hypoxia-inducible factor-1α (HIF-1α) in RA synovium and
fibroblast-like synoviocytes under normoxic and hypoxic conditions. 
(a) Under normoxic conditions, HIF-1α expression in fresh synovial
explants was patchy and confined to some cells in the lining layer. 
(b) When fresh RA tissue explants were cultured in hypoxic conditions
(1% O2), nuclear staining for HIF-1α was readily detected in the lining
cells. (c, d) A similar pattern of expression was seen in fibroblast-like
synoviocytes where under normoxic conditions no HIF-1α staining was
detected (c), whereas under hypoxic conditions intense nuclear
staining was seen maximally at 4–6 hours (d). Reproduced, with
permission, from [91].273
The sequelae of hypoxia and reoxygenation have been
addressed in vascular models, and some limited
experimental evidence has addressed this question in RA
synovium [112]. Interestingly, the vascular models of hypoxia
and reoxygenation have demonstrated a phenomenon that
has been termed preconditioning. This describes a
process whereby a cell or a tissue becomes resistant to
subsequent hypoxic episodes after transient exposure to a
hypoxic episode. The biological basis of preconditioning
continues to be defined, and might involve signaling by
Akt [113] and/or extracellular signal-related kinase 1/2
[114], and possibly an upregulation of PHD-2 during the
hypoxic phase [115]. It is currently not known whether
some form of preconditioning occurs in RA synovitis, and
whether this promotes the survival of cells in this
oxidatively stressed microenvironment.
Therapeutic considerations
Targeting ROS with antioxidants
Various forms of antioxidant therapy have demonstrated
promising results in experimental arthritis models [35–37].
The polyphenolic fraction of green tea containing potent
antioxidants prevents collagen-induced arthritis [116]. The
beneficial effects seem to be due to the catechin
epigallocatechin-3-gallate (EGCG), which inhibits IL-1β-
mediated inflammatory effects, including NOS and NO
production by human chondrocytes [117], and inhibits
MMP activity [118,119].
There is widespread availability and interest in the use of
antioxidant supplementation by patients with inflammatory
arthritis, although proof of efficacy is modest. A traditional
Mediterranean diet relatively high in antioxidants improved
RA disease activity and functional status after 3 months
compared with a standard ‘Western’ diet, although clinical
improvement was not associated with any significant
change in plasma levels of antioxidants [16,120]. In a
separate study of patients with RA, supplementation with
antioxidants vitamin A, E, and C increased plasma
antioxidant levels with a corresponding decrease in
malondialdehyde, a marker of oxidative stress; however, a
clinical response was not reported [121]. Specific
supplementation of oral vitamin E, the major lipid-soluble
antioxidant in human plasma, erythrocytes, and tissue, had
no effect on RA disease activity or indices of inflammation
but did improve pain, suggesting a role in central
analgesia mechanisms [122].
Targeting angiogenesis
It has been proposed that the formation of destructive RA
pannus is dependent on synovial angiogenesis, in a
manner analogous to locally invasive tumors. As is the
case with many tumors, hypoxia has a central role in
regulating this angiogenic process. On this basis,
inhibition of synovial angiogenesis has been proposed as
a rational therapeutic strategy, and several angiogenesis
inhibitors have been shown to have favorable effects in
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Figure 4
Regulation of the hypoxia-inducible factor-1α (HIF-1α) and nuclear factor-κB (NF-κB) pathways by reactive oxygen species (ROS) and cytokine
stimulation. The complex and interrelated activation of these two critical transcription factors is central to most of the processes that sustain
synovitis in rheumatoid arthritis, such as endothelial activation, leukocyte recruitment, angiogenesis, and enhanced cell survival. IL, interleukin;
MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; TNF, tumor necrosis factor.274
animal models (reviewed in [123]). As mentioned earlier, it
has been suggested that the therapeutic responses to
TNF-α inhibition might be attributable, at least in part, to
an inhibition of angiogenesis [99].
An alternative hypothesis suggests that, rather than
representing a tumor-like proliferative process that
outgrows its vascular supply, RA pannus represents a
non-healing synovial wound that is prevented from
resolution by an inadequate vascular supply. Hypoxia has
long been proposed as an important stimulus in wound
healing [124]. Moreover, hypoxia and HIF-1α serve to
stimulate genes that are involved in wound repair and the
formation of granulation tissue, a process critically
dependent on angiogenesis [125–129]. Interestingly, the
expression of HIF-1α protein does not occur during the
initial inflammatory process but becomes evident within
1–5 days of wounding, and seems to have a prominent
role in the subsequent tissue healing. If RA synovitis does
have many of the features of a non-healing wound,
inhibition of angiogenesis would conceptually not
represent an appropriate strategy and indeed might have
deleterious effects, depending on the stage of the
synovitis being treated.
Targeting HIF-1α α and hypoxic cells
Our understanding of cellular and tissue responses to
changes in oxygen tension has increased markedly over
the past decade. The central role of HIF-1α in mediating
hypoxic responses has suggested new therapeutic
opportunities, particularly in cancer and cardiovascular
medicine [130,131]. Small molecules targeting the HIF-1α
pathway are currently being developed and show
considerable promise in cancer models. It should be
noted that many cancer cells overexpress HIF-1α on a
genetic basis, a phenomenon that presumably enhances
their survival in hypoxic environments [131]. It is not clear
whether an analogous situation exists in RA pannus. As
mentioned above, studies evaluating the expression of
HIF-1α in RA synovitis have not provided a consistent
picture, although all studies so far have pointed to the
synovial lining layer as the main site of HIF-1α expression.
It is not clear whether this expression is ‘physiological’, in
response to poor tissue oxygenation, or pathological, as
seen in many tumors. Moreover, chondrocytes that
function in a physiologically hypoxic environment are
critically dependent on HIF-1α for normal development
and maintenance of cartilage integrity [132–136]. Thus,
targeting HIF-1α in an articular disorder such as RA
remains a conceptually challenging proposition requiring
considerably more experimental data.
An alternative approach is to target hypoxic cells by using
their ‘reducing’ intracellular microenvironment to generate
toxic metabolites locally from specific drugs [137]. These
‘bioreductive’ drugs would thus be more toxic to hypoxic
than normoxic cells. Alternatively, such drugs could serve
as carriers for delivering anti-inflammatory compounds to
target tissues. One such bioreductive drug, metronidazole,
has been proposed as potentially being useful for this
purpose, although a controlled clinical trial had produced
mostly disappointing results [138].
Conclusions
Repetitive cycles of hypoxia and reoxygenation, along with
oxidants produced by phagocytic cells such as
macrophages and neutrophils, lead to chronic oxidative
stress in the RA synovial microenvironment. The ROS that
are generated damage proteins, nucleic acids, lipids, and
matrix components, and serve to amplify signaling
pathways that sustain the synovitis. HIF-1α and NF-κB are
key transcription factors that respond to changes in
cellular oxygenation and that orchestrate the expression of
a spectrum of genes that are critical to the persistence of
the synovitis. An understanding of the complex
interactions involved in these pathways may allow the
development of novel therapeutic strategies for RA.
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